Log in

NYSE:BSX - Boston Scientific Stock Price, Forecast & News

$30.61
-0.81 (-2.58 %)
(As of 03/29/2020 01:34 AM ET)
Add
Compare
Today's Range
$29.47
Now: $30.61▼
$31.39
50-Day Range
$25.83
MA: $36.78▼
$43.02
52-Week Range
$24.10
Now: $30.61▼
$46.62
Volume11.23 million shs
Average Volume16.50 million shs
Market Capitalization$42.74 billion
P/E Ratio9.19
Dividend YieldN/A
Beta0.87
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Read More
Boston Scientific logo

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:BSX
Previous Symbol
CUSIP10113710
CIK885725
Webhttp://www.bostonscientific.com/
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.62
Current Ratio0.97
Quick Ratio0.64

Price-To-Earnings

Trailing P/E Ratio9.19
Forward P/E Ratio17.59
P/E Growth1.8

Sales & Book Value

Annual Sales$10.74 billion
Price / Sales3.98
Cash Flow$2.34 per share
Price / Cash Flow13.07
Book Value$9.96 per share
Price / Book3.07

Profitability

EPS (Most Recent Fiscal Year)$1.58
Net Income$4.70 billion
Net Margins43.78%
Return on Equity21.15%
Return on Assets8.47%

Miscellaneous

Employees36,000
Outstanding Shares1,396,190,000
Market Cap$42.74 billion
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

BSX Rates by TradingView

Boston Scientific (NYSE:BSX) Frequently Asked Questions

How has Boston Scientific's stock been impacted by COVID-19 (Coronavirus)?

Boston Scientific's stock was trading at $33.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BSX shares have decreased by 9.6% and is now trading at $30.61. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Boston Scientific?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 1 hold rating, 18 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Boston Scientific.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release its next quarterly earnings announcement on Wednesday, April 22nd 2020. View our earnings forecast for Boston Scientific.

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) released its quarterly earnings data on Wednesday, February, 5th. The medical equipment provider reported $0.46 EPS for the quarter, beating the Zacks' consensus estimate of $0.44 by $0.02. The medical equipment provider had revenue of $2.91 billion for the quarter, compared to analyst estimates of $2.92 billion. Boston Scientific had a return on equity of 21.15% and a net margin of 43.78%. The company's quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter last year, the business earned $0.39 earnings per share. View Boston Scientific's earnings history.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided earnings per share (EPS) guidance of $1.74-1.79 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.79.

What price target have analysts set for BSX?

21 analysts have issued twelve-month price targets for Boston Scientific's shares. Their forecasts range from $30.00 to $58.00. On average, they anticipate Boston Scientific's stock price to reach $47.21 in the next twelve months. This suggests a possible upside of 54.2% from the stock's current price. View analysts' price targets for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company up front cash and commercial-based milestones. Vertiflex’s Superion system is a minimally invasive device to treat patients with lumbar spinal stenosis (LSS). BSX expects the deal to be immaterial to its adjusted EPS through 2020 and accretive thereafter. While we are a little surprised to see BSX enter the spinal surgery market, there probably are synergies with its existing pain business and we see this deal as a typical BSX transaction in which it acquires an asset allowing it to go deeper within a disease state/disorder (in this case chronic pain). We expect BSX’s string of acquisitions over the past ~18 months (including Vertiflex) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating." (5/13/2019)
  • 2. BTIG Research analysts commented, "$42 Story BSX results fell short of Street expectations on a myriad of items. Heading into the print, investors anticipated the paclitaxel and mesh issues but less selling days, a temporary supply issue and a weaker Neuromod result pressured Q1 incrementally. As we anticipated in our preview, BSX guided FY19 revenue growth to the bottom half of the prior range (7-8% from 7- 9%). We revised our estimates accordingly for known pressure points and while there could be upside from high-growth segments (Structural Heart remains likely), our view is that NT significant outperformance by BSX is less likely than it was six months ago. On lower forecasts and a slightly lower multiple, we trim our PT from $45 to $42. Some investors have asked if the growth acceleration story is over. We do not think so but we do think there will be a NT slowdown before potential acceleration." (4/25/2019)

Has Boston Scientific been receiving favorable news coverage?

News articles about BSX stock have been trending very negative this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Boston Scientific earned a news impact score of -3.0 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutBoston Scientific.

Who are some of Boston Scientific's key competitors?

What other stocks do shareholders of Boston Scientific own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include NVIDIA (NVDA), Alibaba Group (BABA), Bank of America (BAC), Walt Disney (DIS), Visa (V), AT&T (T), Netflix (NFLX), Micron Technology (MU), CVS Health (CVS) and salesforce.com (CRM).

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the following people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)
  • Mr. David A. Pierce, Exec. VP & Pres of MedSurg (Age 55)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (9.15%), Capital World Investors (7.73%), Wealth Quarterback LLC (7.26%), State Street Corp (4.32%), Janus Henderson Group PLC (2.78%) and Bollard Group LLC (2.38%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Halliday Hamish, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Williamson Scott, Xin Warren Wang and Yoshiaki Fujimori. View institutional ownership trends for Boston Scientific.

Which institutional investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management LLC, Senator Investment Group LP, Bessemer Group Inc., WCM Investment Management LLC, Bank of New York Mellon Corp, Marshall Wace North America L.P., and AustralianSuper Pty Ltd. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Eric Francis Yves Thepaut, Jeffrey B Mirviss, Jodi Euerle Eddy, John Bradley Sorenson, Joseph Michael Fitzgerald, Maulik Nanavaty, Wendy Carruthers, and Xin Warren Wang. View insider buying and selling activity for Boston Scientific.

Which institutional investors are buying Boston Scientific stock?

BSX stock was acquired by a variety of institutional investors in the last quarter, including Wealth Quarterback LLC, Norges Bank, Jennison Associates LLC, Nuveen Asset Management LLC, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA, State Street Corp, and Strs Ohio. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu, and Williamson Scott. View insider buying and selling activity for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $30.61.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $42.74 billion and generates $10.74 billion in revenue each year. The medical equipment provider earns $4.70 billion in net income (profit) each year or $1.58 on an earnings per share basis. Boston Scientific employs 36,000 workers across the globe. View additional information about Boston Scientific.

What is Boston Scientific's official website?

The official website for Boston Scientific is http://www.bostonscientific.com/.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (NYSE BSX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  852 (Vote Outperform)
Underperform Votes:  733 (Vote Underperform)
Total Votes:  1,585
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Are we seeing the beginning of a new bubble?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel